Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Banque Cantonale Vaudoise

Banque Cantonale Vaudoise increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 69.5% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,970 shares of the biopharmaceutical company’s stock after purchasing an additional 808 shares during the period. Banque Cantonale Vaudoise’s holdings in Regeneron Pharmaceuticals were worth $1,522,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Nordea Investment Management AB grew its stake in Regeneron Pharmaceuticals by 118.1% in the 4th quarter. Nordea Investment Management AB now owns 137,321 shares of the biopharmaceutical company’s stock valued at $105,810,000 after acquiring an additional 74,350 shares during the last quarter. Mackenzie Financial Corp raised its position in Regeneron Pharmaceuticals by 26.8% during the third quarter. Mackenzie Financial Corp now owns 128,623 shares of the biopharmaceutical company’s stock worth $72,321,000 after acquiring an additional 27,205 shares during the last quarter. Lockheed Martin Investment Management Co. acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $2,702,000. Asio Capital LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at about $3,422,000. Finally, Robeco Institutional Asset Management B.V. lifted its holdings in shares of Regeneron Pharmaceuticals by 116.6% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 261,850 shares of the biopharmaceutical company’s stock valued at $202,114,000 after purchasing an additional 140,966 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $632.90 on Friday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $517.39 and a twelve month high of $821.11. The stock has a market capitalization of $66.91 billion, a P/E ratio of 15.42, a PEG ratio of 1.36 and a beta of 0.25. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. The business’s fifty day moving average price is $663.51 and its 200 day moving average price is $728.45.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. The firm had revenue of $3.61 billion during the quarter, compared to the consensus estimate of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The firm’s quarterly revenue was up 19.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $8.22 earnings per share. As a group, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.44 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were given a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio is 9.16%.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the transaction, the director owned 17,503 shares in the company, valued at approximately $12,343,815.72. This trade represents a 0.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on REGN. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday. Royal Bank Of Canada dropped their price target on Regeneron Pharmaceuticals from $762.00 to $707.00 and set a “sector perform” rating for the company in a research report on Monday, May 18th. Piper Sandler cut their price target on Regeneron Pharmaceuticals from $875.00 to $855.00 and set an “overweight” rating for the company in a report on Monday, May 18th. Morgan Stanley upped their price objective on Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the company an “equal weight” rating in a research report on Friday, April 10th. Finally, Citigroup lowered Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $900.00 to $700.00 in a research note on Monday, May 18th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $792.65.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.